Drug Profile
Docetaxel nanoformulation - NanOlogy
Alternative Names: Large Surface Area Microparticle Docetaxel-NanOlogy; LSAM-docetaxel; LSAM-DTX; NanoDoceLatest Information Update: 21 Dec 2023
Price :
$50
*
At a glance
- Originator NanOlogy
- Developer NanOlogy; US Biotest Inc
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I/II Bladder cancer
- Preclinical Renal cancer
Most Recent Events
- 19 Dec 2023 Pharmacodynamics data from preclinical trials in Solid tumours released by NanOlogy
- 07 Mar 2023 NanOlogy has patent protection for Intratumoral administration of LSAM taxanes in combination with systemic administration of immune checkpoint inhibitors (ICIs) in USA
- 07 Mar 2023 Nanology has patents pending for Intratumoral administration of LSAM taxanes in combination with systemic administration of immune checkpoint inhibitors (ICIs) globally